Search hospitals > Washington > Seattle

Seattle Cancer Care Alliance

Claim this profile
Seattle, Washington 98109
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
426 reported clinical trials
43 medical researchers
Photo of Seattle Cancer Care Alliance in SeattlePhoto of Seattle Cancer Care Alliance in SeattlePhoto of Seattle Cancer Care Alliance in Seattle

Summary

Seattle Cancer Care Alliance is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Seattle Cancer Care Alliance is involved with conducting 426 clinical trials across 472 conditions. There are 43 research doctors associated with this hospital, such as Michael J Wagner, MD, Michael Schweizer, Christina S. Baik, and Andrew L. Coveler.

Area of expertise

1Cancer
Global Leader
Seattle Cancer Care Alliance has run 165 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Seattle Cancer Care Alliance has run 59 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage III

Top PIs

Clinical Trials running at Seattle Cancer Care Alliance

Prostate Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Ovarian Cancer
Myelodysplastic Syndrome
Breast Cancer
Bladder Cancer
Chronic Myelomonocytic Leukemia
Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Image of trial facility.

PF-06821497

for Small Cell Lung Cancer

This trial is testing a new drug called PF-06821497 to see if it can help adults with certain hard-to-treat cancers. The drug is taken by mouth and is being studied alone or with other treatments to check its safety and effectiveness in stopping cancer growth.
Recruiting1 award Phase 15 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Seattle Cancer Care Alliance?
Seattle Cancer Care Alliance is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Seattle Cancer Care Alliance is involved with conducting 426 clinical trials across 472 conditions. There are 43 research doctors associated with this hospital, such as Michael J Wagner, MD, Michael Schweizer, Christina S. Baik, and Andrew L. Coveler.
Where is Seattle Cancer Care Alliance located?
**Seattle Cancer Care Alliance** - **Address:** 825 Eastlake Ave E, Seattle, WA.
Who should I call to ask about financial aid or insurance network?
Seattle Cancer Care Alliance (SCCA) provides financial assistance to eligible patients, including those with health insurance, based on income requirements. Patients interested in applying for financial assistance can contact the facility directly or submit an application. For assistance with insurance benefits and care options, SCCA's Patient Financial Services team is available at 800.304.1763.
What insurance does Seattle Cancer Care Alliance accept?
Seattle Cancer Care Alliance (SCCA) accepts a wide range of insurance plans, including but not limited to Premera Blue Cross, Regence BlueShield, Kaiser Permanente, and Medicare. It is important to verify coverage with your insurance provider as some plans, especially those from the Washington Healthplanfinder, may not cover cancer treatment at SCCA. SCCA is also in-network with numerous other insurance providers such as Boeing BCBS, Cigna PPO, Community Health Plan of Washington, and many more. Always confirm that your plan covers the necessary care at SCCA before scheduling an appointment.
What awards or recognition has Seattle Cancer Care Alliance received?
Seattle Cancer Care Alliance (SCCA) ranks among the top ten cancer hospitals in the nation, according to U.S. News & World Report, and is the leading cancer hospital in the Pacific Northwest. It has earned "High Performing" ratings for both colon cancer surgery and lung cancer surgery, showcasing care that surpasses the national average.